Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Tetrahexylammonium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A1 | O15245 | 3/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.57 |
| ▸ | DNM1 | Q05193 | 4/20 | 0.54 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.50 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL7641993 | 1.00 | SLC22A1 (0.62) | SLC22A1ALDH1A1TP53CYP3A4ALOX15 | |
| Tetrabuthylammonium SCHEMBL3643957 | 0.96 | ALDH1A1 (0.61) | SLC22A1ALDH1A1TP53CYP3A4ALOX15 | |
| Phosphoric Acid SCHEMBL28797008 | 0.95 | SLC22A1 (0.62) | SLC22A1ALDH1A1TP53CYP3A4ALOX15 | |
| Phosphoric Acid SCHEMBL19347376 | 0.94 | DNM1 (0.60) | SLC22A1ALDH1A1TP53CYP3A4ALOX15 | |
| Phosphoric Acid SCHEMBL673961 | 0.94 | DNM1 (0.67) | SLC22A1ALDH1A1TP53CYP3A4ALOX15 | |
| Phosphoric Acid SCHEMBL11673407 | 0.94 | DNM1 (0.60) | SLC22A1ALDH1A1TP53CYP3A4ALOX15 | |
| Phosphoric Acid SCHEMBL1204270 | 0.94 | DNM1 (0.67) | SLC22A1ALDH1A1TP53CYP3A4ALOX15 | |
| Phosphoric Acid SCHEMBL692504 | 0.94 | DNM1 (0.67) | SLC22A1ALDH1A1TP53CYP3A4ALOX15 | |
| Tetrabuthylammonium SCHEMBL610140 | 0.93 | SLC22A1 (0.60) | SLC22A1ALDH1A1TP53CYP3A4ALOX15 | |
| Phosphoric Acid SCHEMBL28797009 | 0.93 | SLC22A1 (0.72) | SLC22A1ALDH1A1TP53CYP3A4ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250230296-A1 | POLYVINYLIDENE FLUORIDE RESIN COMPOSITION AND MOLDED BODY | KUREHA CORPORATION (JP) | 2025-07-17 | — | — | US | disclosed |
| EP-4502046-A1 | POLYVINYLIDENE FLUORIDE RESIN COMPOSITION AND MOLDED BODY | Kureha Corporation (JP) | 2025-02-05 | — | — | EP | disclosed |
| CN-118946631-A | Polyvinylidene fluoride resin composition and molded article | 株式会社吴羽 | 2024-11-12 | — | — | CN | disclosed |
| WO-2024063026-A1 | PHOSPHORIC ACID-CONTAINING MODIFIED METAL OXIDE SOL AND METHOD FOR PRODUCING SAME | 日産化学株式会社 | 2024-03-28 | — | — | WO | disclosed |
| WO-2023181878-A1 | POLYVINYLIDENE FLUORIDE RESIN COMPOSITION AND MOLDED BODY | 株式会社クレハ | 2023-09-28 | — | — | WO | disclosed |
| US-10317410-B2 | Multi-dimensional chromatographic methods for separating N-glycans | MOMENTA PHARMACEUTICALS, INC. (US) | 2019-06-11 | — | — | US | disclosed |
| US-9933432-B2 | Multi-dimensional chromatographic methods for separating N-glycans | MOMENTA PHARMACEUTICALS, INC. (US) | 2018-04-03 | — | — | US | disclosed |
| US-20170212129-A1 | MULTI-DIMENSIONAL CHROMATOGRAPHIC METHODS FOR SEPARATING N-GLYCANS | MOMENTA PHARMACEUTICALS, INC. | 2017-07-27 | — | — | US | disclosed |
| US-20160356783-A1 | MULTI-DIMENSIONAL CHROMATOGRAPHIC METHODS FOR SEPARATING N-GLYCANS | MOMENTA PHARMACEUTICALS, INC. | 2016-12-08 | — | — | US | disclosed |
| US-9448147-B2 | Multi-dimensional chromatographic methods for separating N-glycans | MOMENTA PHARMACEUTICALS, INC. (US) | 2016-09-20 | — | — | US | disclosed |
| US-8304250-B2 | Multi-dimensional chromatographic methods for separating N-glycans | MOMENTA PHARMACEUTICALS, INC. (US) | 2012-11-06 | — | — | US | disclosed |
| EP-2297172-B1 | PROCESS FOR PRODUCING NANOPARTICLES | 3M INNOVATIVE PROPERTIES CO (US) | 2012-06-27 | — | — | EP | disclosed |
| EP-2297172-A2 | PROCESS FOR PRODUCING NANOPARTICLES | 3M Innovative Properties Company (US) | 2011-03-23 | — | — | EP | disclosed |
| EP-2291460-A2 | SURFACE-MODIFIED NANOPARTICLES | 3M Innovative Properties Company (US) | 2011-03-09 | — | — | EP | disclosed |
| US-20110046404-A1 | PROCESS FOR PRODUCING NANOPARTICLES | 3M INNOVATIVE PROPERTIES COMPANY | 2011-02-24 | — | — | US | disclosed |
| US-20110039947-A1 | SURFACE-MODIFIED NANOPARTICLES | 3M INNOVATIVE PROPERTIES COMPANY | 2011-02-17 | — | — | US | disclosed |
| US-20100151584-A1 | MULTI-DIMENSIONAL CHROMATOGRAPHIC METHODS FOR SEPARATING N-GLYCANS | MOMENTA PHARMACEUTICALS, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| WO-2010059812-A1 | SURFACE-MODIFIED METAL PHOSPHATE NANOPARTICLES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2010-05-27 | — | — | WO | disclosed |
| WO-2009137595-A2 | PROCESS FOR PRODUCING NANOPARTICLES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2009-11-12 | — | — | WO | disclosed |
| WO-2009137592-A2 | SURFACE-MODIFIED NANOPARTICLES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2009-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10317410-B2 | Multi-dimensional chromatographic methods for separating N-glycans | FUT5, B3GNT2, ENGASE | SLC22A1 1085/4885ALDH1A1 3974/4885TP53 3713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.